Inhaltsbereich
| 48 Einträge | 1, 2, 3 › » |
Seite 1 / 3
 Druckansicht
|
| Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression. |
| Fuereder T, Stift J, Kuehrer I, Stranzl N, Hoeflmayer D, Kornek G, Scheithauer W |
| European journal of clinical investigation. 2014 Sep 26. doi: 10.1111/eci.12329 |
| PMID: 25145842 |
| Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. |
| Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Jun 28. pii: 1078-0432.CCR-10-1659. doi: 10.1158/1078-0432.CCR-10-1659 |
| PMID: 21712451 |
| Sphingosine kinase 1 is a relevant molecular target in gastric cancer. |
| Fuereder T, Hoeflmayer D, Jaeger-Lansky A, Rasin-Streden D, Strommer S, Fisker N, Hansen BJ, Crevenna R, Wacheck V |
| Anti-cancer drugs. 2011 Feb 28. |
| PMID: 21360847 |
| Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. |
| Werzowa J, Koehrer S, Strommer S, Cejka D, Fuereder T, Zebedin E, Wacheck V |
| The Journal of investigative dermatology. 2010 Nov 4. pii: jid2010327. doi: 10.1038/jid.2010.327 |
| PMID: 21048785 |
| mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. |
| Fuereder T, Jaeger-Lansky A, Hoeflmayer D, Preusser M, Strommer S, Cejka D, Koehrer S, Crevenna R, Wacheck V |
| Cancer letters. 2010 May 14. pii: S0304-3835(10)00219-3. doi: 10.1016/j.canlet.2010.04.015 |
| PMID: 20471160 |
| Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. |
| Jaeger-Lansky A, Cejka D, Ying L, Preusser M, Hoeflmayer D, Fuereder T, Koehrer S, Wacheck V |
| Cancer biology & therapy. 2010 Jun 18. pii: 11805 |
| PMID: 20404549 |
| FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. |
| Cejka D, Kuntner C, Preusser M, Fritzer-Szekeres M, Fueger BJ, Strommer S, Werzowa J, Fuereder T, Wanek T, Zsebedics M, Mueller M, Langer O, Wacheck V |
| British journal of cancer. 2009 May 12. pii: 6605076. doi: 10.1038/sj.bjc.6605076. pmc: PMC2695687 |
| PMID: 19436299 |
| mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. |
| Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V |
| Anticancer research. 2009 Feb 4. |
| PMID: 19189667 |
| Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002. |
| Werzowa J, Cejka D, Fuereder T, Dekrout B, Thallinger C, Pehamberger H, Wacheck V, Pratscher B |
| The British journal of dermatology. 2008 Dec 16. pii: BJD8991. doi: 10.1111/j.1365-2133.2008.08991.x |
| PMID: 19120326 |
| Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. |
| Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, Fuereder T, Wacheck V |
| Cancer biology & therapy. 2008 Sep 2. pii: 6416 |
| PMID: 18708754 |
| Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. |
| Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, Wang X, Gruber D, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Wacheck V |
| Transplantation. 2007 Feb 23. doi: 10.1097/01.tp.0000252780.42104.95. pii: 00007890-200702270-00010 |
| PMID: 17318075 |
| Immunotherapy for head and neck squamous cell carcinoma. |
| Fuereder T |
| Memo. 2016 Jun 20. doi: 10.1007/s12254-016-0270-8. pii: 270 |
| PMID: 27429658 |
| The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. |
| Russmueller G, Seemann R, Weiss K, Stadler V, Speiss M, Perisanidis C, Fuereder T, Willinger B, Sulzbacher I, Steininger C |
| Scientific reports. 2016 Aug 17. pii: srep31604. doi: 10.1038/srep31604 |
| PMID: 27530150 |
| Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer. |
| Posch D, Fuchs H, Kornek G, Grah A, Pammer J, Aretin MB, Fuereder T |
| Scientific reports. 2016 Sep 6. pii: srep32946. doi: 10.1038/srep32946 |
| PMID: 27597175 |
| The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. |
| Kiesewetter B, Raderer M, Prager GW, Fuereder T, Marosi C, Preusser M, Krainer M, Locker GJ, Brodowicz T, Zielinski CC |
| ESMO open. 2017 Jul 16. doi: 10.1136/esmoopen-2017-000166. pii: esmoopen-2017-000166. pmc: PMC5519788 |
| PMID: 28761758 |
| Metal drugs become targeted. |
| Fuereder T, Berger W |
| ESMO open. 2017 Aug 17. doi: 10.1136/esmoopen-2017-000239. pii: esmoopen-2017-000239. pmc: PMC5604710 |
| PMID: 29225925 |
| Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer. |
| Fuchs H, Pammer J, Minichsdorfer C, Posch D, Kornek G, Aretin MB, Fuereder T |
| Medical oncology (Northwood, London, England). 2018 Feb 7. doi: 10.1007/s12032-018-1087-6. pii: 10.1007/s12032-018-1087-6 |
| PMID: 29411154 |
| Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. |
| Prager GW, Unseld M, Waneck F, Mader R, Wrba F, Raderer M, Fuereder T, Staber P, Jäger U, Kieler M, Bianconi D, Hoda MA, Baumann L, Reinthaller A, Berger W, Grimm C, Kölbl H, Sibilia M, Müllauer L, Zielinski C |
| Oncotarget. 2019 Jan 29. doi: 10.18632/oncotarget.26604. pii: 26604. pmc: PMC6398177 |
| PMID: 30847023 |
| Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer. |
| Beer L, Hochmair M, Haug AR, Schwabel B, Kifjak D, Wadsak W, Fuereder T, Fabikan H, Fazekas A, Schwab S, Mayerhoefer ME, Herold C, Prosch H |
| Clinical nuclear medicine. 2019 Apr 19. doi: 10.1097/RLU.0000000000002603 |
| PMID: 31021918 |
| Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. |
| Kieler M, Unseld M, Bianconi D, Waneck F, Mader R, Wrba F, Fuereder T, Marosi C, Raderer M, Staber P, Berger W, Sibilia M, Polterauer S, Müllauer L, Preusser M, Zielinski CC, Prager GW |
| ESMO open. 2019 Jul 17. doi: 10.1136/esmoopen-2019-000538. pii: esmoopen-2019-000538. pmc: PMC6677998 |
| PMID: 31423337 |
| 48 Einträge | 1, 2, 3 › » |
Seite 1 / 3
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
